TIPIFARNIB

Search structure
Synonyms:
Status: Phase 3
Entry Type: Small molecule
Molecule Category: UNKNOWN
UNII: MAT637500A

Structure
InChI Key PLHJCIYEEKOWNM-HHHXNRCGSA-N
Smile Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2c(c1)c(-c1cccc(Cl)c1)cc(=O)n2C
InChI
InChI=1S/C27H22Cl2N4O/c1-32-16-31-15-25(32)27(30,18-6-9-20(28)10-7-18)19-8-11-24-23(13-19)22(14-26(34)33(24)2)17-4-3-5-21(29)12-17/h3-16H,30H2,1-2H3/t27-/m1/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C27H22Cl2N4O
Molecular Weight 489.41
AlogP 5.5
Hydrogen Bond Acceptor 5.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 4.0
Polar Surface Area 65.84
Molecular species NEUTRAL
Aromatic Rings 5.0
Heavy Atoms 34.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Protein farnesyltransferase inhibitor PubMed
Primary Target
farnesyltransferase, CAAX box, beta
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Cytochrome P450 Cytochrome P450 family 3 Cytochrome P450 family 3A Cytochrome P450 3A4
- 1700-4060 - - -
Enzyme Transferase
2-100 1-8 - - 2
Enzyme
2-100 1-8 - - 2

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Leukemia, Erythroblastic, Acute 3 D004915 ClinicalTrials
Leukemia, Myeloid, Acute 3 D015470 ClinicalTrials
Leukemia, Myeloid, Acute 3 D015470 ClinicalTrials
Myelodysplastic Syndromes 3 D009190 ClinicalTrials
Leukemia, Myeloid, Acute 3 D015470 ClinicalTrials
Leukemia, Myelomonocytic, Acute 3 D015479 ClinicalTrials
Leukemia, Monocytic, Acute 3 D007948 ClinicalTrials
Thrombocythemia, Essential 2 D013920 ClinicalTrials
Glioblastoma 2 D005909 ClinicalTrials
Oligodendroglioma 2 D009837 ClinicalTrials
Polycythemia Vera 2 D011087 ClinicalTrials
Primary Myelofibrosis 2 D055728 ClinicalTrials
Medulloblastoma 2 D008527 ClinicalTrials
Carcinoma, Non-Small-Cell Lung 2 D002289 ClinicalTrials
Breast Neoplasms 2 D001943 ClinicalTrials
Neuroectodermal Tumors, Primitive 2 D018242 ClinicalTrials
Astrocytoma 2 D001254 ClinicalTrials
Melanoma 2 D008545 ClinicalTrials
Pancreatic Neoplasms 2 D010190 ClinicalTrials
Gliosarcoma 2 D018316 ClinicalTrials
Leukemia, Myelomonocytic, Chronic 2 D015477 ClinicalTrials
Lymphoma, Mantle-Cell 2 D020522 ClinicalTrials
Breast Neoplasms 2 D001943 ClinicalTrials
Urinary Bladder Neoplasms 2 D001749 ClinicalTrials
Thyroid Neoplasms 2 D013964 ClinicalTrials
Breast Neoplasms 2 D001943 ClinicalTrials
Prostatic Neoplasms, Castration-Resistant 2 D064129 ClinicalTrials
Lung Neoplasms 2 D008175 ClinicalTrials
Leukemia, Large Granular Lymphocytic 2 D054066 ClinicalTrials
Head and Neck Neoplasms 2 D006258 ClinicalTrials
Leukemia, Lymphocytic, Chronic, B-Cell 2 D015451 ClinicalTrials
Leukemia, Myelomonocytic, Juvenile 2 D054429 ClinicalTrials
Inflammatory Breast Neoplasms 2 D058922 ClinicalTrials
Colorectal Neoplasms 2 D015179 ClinicalTrials
Urinary Bladder Neoplasms 2 D001749 ClinicalTrials
Breast Neoplasms, Male 1 D018567 ClinicalTrials
Leukemia 1 D007938 ClinicalTrials
Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 D015464 ClinicalTrials
Central Nervous System Neoplasms 1 D016543 ClinicalTrials
Neoplasms 1 D009369 ClinicalTrials
Multiple Myeloma 1 D009101 ClinicalTrials
Neoplasms 1 D009369 ClinicalTrials
Myeloproliferative Disorders 1 D009196 ClinicalTrials

Related Entries

Scaffolds

Cross References

Resources Reference
CAS NUMBER 192185-72-1
ChEBI 141969
ChEMBL CHEMBL289228
DrugBank DB04960
EPA CompTox DTXSID5041140
FDA SRS MAT637500A
Guide to Pharmacology 8025
PDB JAN
PubChem 159324
SureChEMBL SCHEMBL21544535
ZINC ZINC000024809155
CONTENTS